Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients  

作　　者：Li-Yang Meng Chao-Ting Yang Jian-Feng Bao Jin-Song Huang 

机构地区：[1]The Fourth Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang Province,China [2]Department of Hepatology,Hangzhou Xixi Hospital,Zhejiang University School of Medicine,Hangzhou 310023,Zhejiang Province,China

出　　处：《World Journal of Gastroenterology》2024年第26期3261-3263,共3页世界胃肠病学杂志（英文版）

基　　金：Supported by Biomedical Enterprise Project of Hangzhou Science and Technology Bureau,No.2021WJCY061 and No.2022WJC230.

摘　　要：This letter to the editor relates to the study entitled“Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B:A real-world study”,which was recently published by Peng et al.Hepatitis B virus infection represents a significant health burden worldwide and can lead to cirrhosis and even liver cancer.The antiviral drugs currently used to treat patients with chronic hepatitis B infection still have many side effects,so it is crucial to identify safe and effective drugs to inhibit viral replication.

关 键 词：Tenofovir amibufenamide Chronic hepatitis B Non-alcoholic fatty liver disease Alanine transaminase normalization Virological response 

分 类 号：R512.62[医药卫生—内科学]